Gemcitabine oral - INNOPHARMAX

Drug Profile

Gemcitabine oral - INNOPHARMAX

Alternative Names: D07001; D07001-F4; Gemcitabine HCl - INNOPHARMAX; Inno-D07001

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator INNOPHARMAX
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 02 Dec 2016 Pharmacokinetics, adverse events and preliminary efficacy data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Solid-tumours in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top